NCT05862883View on ClinicalTrials.gov

Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

PHASE2CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
COVID-19 Respiratory Infection
Interventions
DRUG

Rutan 25 mg

"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."

OTHER

Control group

Taking basic therapy without Rutan

Trial Locations (1)

100194

Tashkent Institute of Virology, Tashkent

All Listed Sponsors
lead

Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan

OTHER_GOV